777 replies to this topic

[ImmInst]

BioTime Inc.: BioTime Announces First Quarter 2014 Results and Recent ...
The Wall Street Transcript - 3 hours ago

ALAMEDA, Calif.--(BUSINESS WIRE)--May 12, 2014-- BioTime, Inc. (NYSE MKT: BTX) today reported financial results for the first quarter ended March 31, 2014 and highlighted recent corporate accomplishments.

BioTime Announces First Quarter 2014 Results and Recent Developments - Wall Street Journal
BioTime (BTX) Posts Quarterly Results - The Legacy

View the full article

[ImmInst]

BioTime Announces First Quarter 2014 Results and Recent Developments
Wall Street Journal - May 12, 2014

BioTime, Inc. (NYSE MKT: BTX) today reported financial results for the first quarter ended March 31, 2014 and highlighted recent corporate accomplishments.

View the full article

[ImmInst]

Asterias Biotherapeutics Announces Distribution Date of BioTime Warrants and ...
MarketWatch - Sep 29, 2014

MENLO PARK, Calif., Sep 29, 2014 (BUSINESS WIRE) -- Asterias Biotherapeutics, Inc. ASTY, +10.09% announced today that on October 1, 2014 the company will distribute 8,000,000 warrants to purchase common shares of BioTime, Inc. (the “BioTime ...

View the full article

[ImmInst]

LifeMap Solutions Adds Chief Technology Officer to Leadership Team
MarketWatch - 1 hour ago

ALAMEDA, Calif., Oct 01, 2014 (BUSINESS WIRE) -- BioTime, Inc. (nyse mkt:BTX) and its subsidiary LifeMap Solutions, Inc., a medical technology company, today announced significant additions to the LifeMap Solutions management team.

View the full article

[ImmInst]

BioTime's Subsidiary OncoCyte Corporation Announces Completion of Multi-Site ...
MarketWatch - 2 hours ago

ALAMEDA, Calif., Oct 03, 2014 (BUSINESS WIRE) -- BioTime, Inc. (nyse mkt:BTX), and its subsidiary OncoCyte Corporation today announced that OncoCyte's collaborators at The Wistar Institute have completed enrollment of a large, multi-site study ...

View the full article

[ImmInst]

BioTime's Subsidiary OncoCyte Corporation Announces Completion of Multi-Site ...
Business Wire (press release) - Oct 3, 2014

BUSINESS WIRE)--BioTime, Inc. (NYSE MKT: BTX), and its subsidiary OncoCyte Corporation today announced that OncoCyte's collaborators at The Wistar Institute have completed enrollment of a large, multi-site study evaluating a blood-based lung cancer ...

View the full article

[ImmInst]

BioTime's Subsidiary Cell Cure Neurosciences Ltd. Files an IND with the FDA ...
Rock Hill Herald (press release) - 1 hour ago

ALAMEDA, Calif. & JERUSALEM - BioTime, Inc. (NYSE MKT: BTX), HBL Hadasit Bio-Holdings Ltd. (TASE: HDST, OTC: HADSY) and Cell Cure Neurosciences Ltd.

View the full article

[ImmInst]

BioTime, Inc. and Subsidiaries to Raise $31 Million Through Sales of Common ...
Business Wire (press release) - 2 hours ago

ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT:BTX) today announced that it has agreed to sell up to an aggregate of 9,431,398 common shares, in a registered direct offering at an offering price of $3.12 per share.

BioTime Inc.: Michael H. Mulroy and Stephen L. Cartt Joining BioTime Board of ... - The Wall Street Transcript

View the full article

[ImmInst]

BioTime Is Right On Time: Files IND For AMD
Seeking Alpha (registration) - 5 minutes ago

This article is a follow up to my prior article, BioTime Joins Advanced Cell Technology In The AMD Race. BioTime, Inc. and Advanced Cell Technology, Inc. (OTCQB:ACTC) are competitors in the stem cell space. Both have platforms that use Retinal Pigment ...

BioTime's Subsidiary Cell Cure Neurosciences Ltd. Files an IND with the FDA ... - Rock Hill Herald (press release)

View the full article

[ImmInst]

BioTime Is Right On Time: Files IND For AMD
Seeking Alpha (registration) - 17 hours ago

This article is a follow up to my prior article, BioTime Joins Advanced Cell Technology In The AMD Race. BioTime, Inc. and Advanced Cell Technology, Inc. (OTCQB:ACTC) are competitors in the stem cell space. Both have platforms that use Retinal Pigment ...

View the full article

[ImmInst]

BioTime Inc.: Michael H. Mulroy and Stephen L. Cartt Joining BioTime Board of ...
The Wall Street Transcript - Oct 6, 2014

ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 6, 2014-- BioTime, Inc. (NYSE MKT:BTX) announced today that Michael H. Mulroy and Stephen L. Cartt are joining its Board of Directors.

View the full article

[ImmInst]

BioTime, Inc. and Subsidiaries to Raise $31 Million Through Sales of Common ...
Rock Hill Herald (press release) - Oct 6, 2014

ALAMEDA, Calif. - BioTime, Inc. (NYSE MKT:BTX) today announced that it has agreed to sell up to an aggregate of 9,431,398 common shares, in a registered direct offering at an offering price of $3.12 per share.

View the full article

[ImmInst]

BioTime, Inc. Closes $31 Million Financing
Rock Hill Herald (press release) - 2 hours ago

ALAMEDA, Calif. - BioTime, Inc. (NYSE MKT: BTX) today announced that it has closed the equity financing it disclosed on October 3, 2014, through which BioTime received $29,425,961 and certain subsidiaries received approximately $1,558,905 from the ...

View the full article

[ImmInst]

BioTime, Inc. (BTX): Neal C. Bradsher Keeps Buying More Shares
Insider Monkey (blog) - 4 hours ago

As a new filing with the Securities and Exchange revealed, Neal C. Bradsher's Broadwood Capital has acquired a significant position in BioTime, Inc. (NYSEMKT:BTX) and raised its stake to nearly 17.90 million shares of the company. Broadwood acquired ...

View the full article

[ImmInst]

BioTime, Inc. (NYSEMKT:BTX) Closes Equity Financing Worth $31 Million
WallStreetPR (blog) - 1 hour ago

Boston, MA 10/10/2014 (wallstreetpr) - According to reports, BioTime, Inc. (NYSEMKT:BTX) announced that it recently closed equity financing worth $31 million.

View the full article

[ImmInst]

BioTime, Inc. Closes $31 Million Financing
Rock Hill Herald (press release) - Oct 9, 2014

ALAMEDA, Calif. - BioTime, Inc. (NYSE MKT: BTX) today announced that it has closed the equity financing it disclosed on October 3, 2014, through which BioTime received $29,425,961 and certain subsidiaries received approximately $1,558,905 from the ...

View the full article

[ImmInst]

BioTime, Inc. Closes $31 Million Financing
Business Wire (press release) - Oct 9, 2014

BUSINESS WIRE)--BioTime, Inc. (NYSE MKT: BTX) today announced that it has closed the equity financing it disclosed on October 3, 2014, through which BioTime received $29,425,961 and certain subsidiaries received approximately $1,558,905 from the ...

View the full article

[ImmInst]

LifeMap Sciences, a Subsidiary of BioTime, Announces Release of MalaCards ...
Business Wire (press release) - Oct 6, 2014

ALAMEDA, Calif.--(BUSINESS WIRE)--LifeMap Sciences, Inc., a subsidiary of BioTime, Inc., announced today the recent release of MalaCards, Version 1.06.

View the full article

[ImmInst]

BioTime: Recent News Hints At Positive Developments
Seeking Alpha (registration) - 3 hours ago

The company has consolidated into one company and remains under the radar, but not for long. One driver could be the recent IND filing regarding dry-AMD (Age-Related Macular Degeneration).

View the full article

[ImmInst]

BioTime Inc.: Asterias Biotherapeutics to Report Third Quarter Results on ...
The Wall Street Transcript - 1 hour ago

MENLO PARK, Calif., Oct. 31, 2014 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced that it will release third quarter financial and operating ...

View the full article

[ImmInst]

FDA clears BioTime's IND for AMD stem cell therapeutic candidate (BTX)
Seeking Alpha (registration) - 3 hours ago

The FDA approves BioTime (NYSEMKT:BTX) subsidiary Cell Cure Neurosciences' IND for OpRegen, its human embryonic stem cell-derived (hESC) therapeutic candidate for the treatment of age-related macular degeneration (AMD) or geographic atrophy ...

Most Popular Stories - Rock Hill Herald (press release)

View the full article

[ImmInst]

FDA clears BioTime's IND for AMD stem cell therapeutic candidate (BTX)
Seeking Alpha (registration) - 14 hours ago

The FDA approves BioTime (NYSEMKT:BTX) subsidiary Cell Cure Neurosciences' IND for OpRegen, its human embryonic stem cell-derived (hESC) therapeutic candidate for the treatment of age-related macular degeneration (AMD) or geographic atrophy ...

View the full article

[ImmInst]

UPDATE: BioTime Receives Authorization To Begin Pivotal Human Clinical Trial ...
Benzinga - 2 hours ago

BioTime, Inc. (NYSE MKT: BTX) today reported that it has received authorization to begin its pivotal human clinical trial of Renevia™ in Europe.

View the full article

[ImmInst]

UPDATE: BioTime Receives Authorization To Begin Pivotal Human Clinical Trial ...
Benzinga - 23 hours ago

BioTime, Inc. (NYSE MKT: BTX) today reported that it has received authorization to begin its pivotal human clinical trial of Renevia™ in Europe.

View the full article

[ImmInst]

Closing Bell Reports: Asterias Biotherapeutics, Inc. (AST), Cyberonics Inc ...
WallStreet Scope - 2 hours ago

BioTime, Inc. (BTX) of the Healthcare sector located in the USA is down -1.75%, a change from open of -1.1700% ($-0.06 per share) at the close of the bell.

View the full article

[ImmInst]

BioTime Reports Third Quarter Results and Recent Progress
Broadway World - 3 hours ago

BioTime Reports Third Quarter Results and Recent Progress BioTime, Inc. (NYSE MKT: BTX), the leader in developing pluripotent stem-cell therapies and other technologies designed to address major unmet medical needs, today reported financial results for ...

BioTime (BTX) Announces Quarterly Results - WKRB News

View the full article

[ImmInst]

BioTime (BTX) Announces Quarterly Results
WKRB News - 22 hours ago

BioTime, Inc. logo BioTime (NYSE:BTX) posted its quarterly earnings results on Monday. The company reported ($0.12) EPS for the quarter, American Banking News.

View the full article

[ImmInst]

A Timely Interview With BioTime's CEO And His Chief Commercial Officer
Seeking Alpha (registration) - 35 minutes ago

Prior to joining BioTime in 2011, Dr. Tew was co-founder, President, and CEO of Glycosan BioSystems, Inc., which was acquired by a BioTime subsidiary several years ago. At Glycosan, Dr. Tew was instrumental in the development and commercialization of ...

View the full article

[ImmInst]

BioTime: Backed By Dubious Stock Promoters
Seeking Alpha - Apr 26, 2012

In our previous article, we discussed how BioTime, Inc. (NYSEMKT:BTX) has used press releases, particularly regarding the creation and acquisition of numerous subsidiaries, to boost the company's share price.

View the full article

[ImmInst]

UPDATE: BioTime Appoints Angus C. Russell To Bd Of Directors
Benzinga - 4 hours ago

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Angus C. Russell, former Chief Executive Officer of Shire plc, has been appointed to BioTime's Board ...

BioTime Subsidiary ES Cell International and GE Healthcare Cross-License ... - Business Wire (press release)
BioTime Appoints Angus C. Russell to Board of Directors - MarketWatch

View the full article